The nice people at the Transfusion Evidence Alert sent their update today. As they do they send too much for my poor brain to take in at one sitting, but it is all useful stuff…
TOP ARTICLES
Trial of Intravenous Immune Globulin in Dermatomyositis.Aggarwal, R., et al. (2022). The New England Journal of Medicine.
A Randomized, Double-Blind, Placebo-Controlled Trial of the Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis. Bril, V., et al. (2022). Neurology. [Record in progress].
Tranexamic acid dose-response relationship for antifibrinolysis in postpartum haemorrhage during Caesarean delivery: TRACES, a double-blind, placebo-controlled, multicentre, dose-ranging biomarker study.Ducloy-Bouthors, A.S., et al. (2022). British Journal of Anaesthesia.
Strategies to Reduce Diagnostic Blood Loss and Anemia in Hospitalized Patients: A Scoping Review. François, T., et al. (2022). Pediatric Critical Care Medicine
Transfusion-transmitted arboviruses: Update and systematic review.Giménez-Richarte, A., et al. (2022). PLoS Neglected Tropical Diseases.
The Untrained Public's Ability to Apply the Layperson Audiovisual Assist Tourniquet vs a Combat Application Tourniquet: A Randomized Controlled Trial.Goolsby, C., et al. (2022). Journal of the American College of Surgeons. [Record in progress].Postpartum hemorrhage drills or simulations and adverse outcomes: a systematic review and Bayesian meta-analysis.Mendez-Figueroa, H., et al. (2022). The Journal of Maternal-Fetal & Neonatal Medicine. [Record in progress].
Effect of Autotransfusion in HCC Surgery on Survival and Recurrence: A Systematic Review and Meta-Analysis.Murtha-Lemekhova, A. et al. (2022). Cancers.
Efficacy of therapeutic plasma exchange in severe COVID-19 disease: A meta-analysis.Prakash, S., et al. (2022). Vox sanguinis. [Record progress].
ARTICLE OF THE MONTH Systematic review and meta-analysis of intravenous iron-carbohydrate complexes in HFrEF patients with iron deficiency.Sindone, A., et al. (2022). ESC Heart Failure.PICO Summary available +++++ |
No comments:
Post a Comment